Physician profile
Tracey C Gaslin
NPI 1578777314
$79,150.36
in general payments reported to CMS, 2019-2025
18 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,272 · 2022: $12K · 2023: $18K · 2024: $24K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $9,942 · Food and Beverage: $6,706 · Education: $55.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,144.68 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,727.00 |
| Travel and Lodging | $9,941.72 |
| Food and Beverage | $6,705.67 |
| Education | $55.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $35,764.67 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $16,733.05 | 2024-2025 | |
| Genentech USA, INC. | $14,571.64 | 2021-2025 | Hemlibra |
| Sanofi US Services INC. | $5,248.00 | 2025 | |
| Pfizer INC. | $3,650.09 | 2021-2025 | |
| Novo Nordisk INC | $1,162.95 | 2021-2025 | |
| Incyte Corporation | $521.78 | 2021-2025 | Monjuvi, Jakafi, Zynyz |
| Bayer Healthcare Pharmaceuticals INC. | $430.81 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $231.42 | 2021-2025 | Advate, Adynovate, Vonvendi |
| Csl Behring | $188.61 | 2021-2024 | Hemgenix, Afstyla, Idelvion |
| Biomarin Pharmaceutical INC. | $177.90 | 2021-2022 | |
| Genentech, INC. | $138.65 | 2023-2025 | Hemlibra |
| Hema Biologics, LLC | $133.44 | 2021-2025 | Sevenfact, Sevenfact |
| Octapharma USA, INC. | $55.82 | 2021-2025 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Kedrion Biopharma, INC. | $54.87 | 2023-2024 | Koate, Albuked, Kedrab |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $36.41 | 2022 | |
| Rigel Pharmaceuticals, INC. | $32.44 | 2024 | Rezlidhia, Tavalisse |
| Coherus Oncology, INC. | $17.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracey Gaslin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.